PhorMed

Neutral
BETA

Utilizing gene therapy to target cancer and mutated cells

Analytics

Raised to Date: $1,069,890

Aggregate Commitments $
Platform

StartEngine

Start Date

12/06/2019

Close Date

04/30/2021

Min. Goal

$10,000

Max. Goal

$1,070,000

Min. Investment

$250

Security Type

Equity - Common

Funding Type

RegCF

Series

Pre-Seed

Pre-Money Valuation

$39,000,000

Weekly Commitments $
Status

Active

Reporting Date

01/20/2021

Days Remaining

98

% of Min. Goal

10,699%

% of Max. Goal

100%

Likelihood of Max
Avg. Daily Raise

$2,603

# of Investors

2,445

Momentum
Location
Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B2C

Margin

High

Capital Intensity

High

Business Type

Growth

PhorMed, with a pre-money valuation of $39 million, is raising funds on StartEngine.It is a biopharmaceutical company that is changing the face of genomic medicine. PhorMed uses gene therapy to target and treat cancer cells and mutated cells, and develops a treatment for patients suffering from Hodgkin’s Lymphoma, Parkinson’s Disease, and Acute Myeloid Leukemia. PhorMed was founded by McCoy Moretz Richard L. Chang and others. The proceeds of the current crowdfunding round, with a minimum target of $10,000 and a maximum target of $107,000, will be used for the Phase 2 clinical trials of the drug. PhorMed uses a leading technology, RP-323, as its gene repair therapy. The drug has completed Phase 1 of the clinical study and has generated positive outcomes.

Ratings

last updated 01/21/2021

Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.
Other Deals

Millennial Fertility Co. on NetCapital

The Millennial Fertility Co. team has been selected as a “Deal to Watch” by KingsCrowd. This distinction is…

Crowd
Biopact on Equifund CFP

Biopact has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected…

Crowd
Neurotez Inc. on NetCapital

Neurotez has been selected as a “Deal To Watch” by KingsCrowd. This distinction is reserved for deals selected…

Crowd
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add PhorMed on StartEngine
Follow company
Follow PhorMed on StartEngine